+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07815665

Randomized Study Comparing Ivonescimab Plus Enfortumab Vedotin to Pembrolizumab Plus Enfortumab Vedotin in Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Led by Summit Therapeutics · Updated on 2026-09-11

800

Participants Needed

7

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase 23 clinical trial to study treatments for patients with previously untreated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. The study evaluates and compares the combination of ivonescimab with enfortumab vedotin against pembrolizumab combined with enfortumab vedotin. This research aims to find the best dose and assess the safety and effectiveness of these therapies in this patient population. The trial is divided into two parts. In Phase 2, participants are randomly assigned to receive one of two different doses of ivonescimab combined with enfortumab vedotin to determine the recommended dose for Phase 3. In Phase 3, participants are randomized to receive either the recommended dose of ivonescimab plus enfortumab vedotin or pembrolizumab plus enfortumab vedotin. Both treatments are given according to their dosing schedules, with Phase 2 focusing on dose finding and Phase 3 on comparing efficacy and safety. Participants will be involved in the study through treatment administration and regular monitoring. Researchers will assess safety and effectiveness by tracking disease progression, survival, and any side effects from the start of treatment until several years after. The study includes evaluations up to 3 to 4 years, with careful follow-up after treatment ends to measure outcomes and ensure participant safety throughout the course of the trial.

CONDITIONS

Brief Title

A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Research Team

S

Summit Clinical Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here